CBIO — CRESCENT BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1253689 ·
Last close
$13.99
Market Cap
$519.64M
52W High
$27.41
52W Low
$8.72
ADV30
418,297
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,364,000 | -24,837,000 | 182,758,000 | 171,593,000 | 19,503,000 |
| Mar 2026 | 1,039,000 | — | -24,729,000 | -23,283,000 | 199,130,000 | 189,163,000 | 15,283,000 |
| Dec 2025 | 10,844,000 | — | -91,492,000 | -92,397,000 | 240,293,000 | 213,192,000 | 37,281,000 |
| Sep 2025 | 0 | — | -25,885,000 | -24,607,000 | 138,269,000 | 133,265,000 | 21,628,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,679,000
Investing CF
$-79,169,000
Financing CF
$170,797,000
CapEx
$-80,939,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-6.72
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-219,929,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-163,124,000
Pretax Income TTM
$-163,124,000
Interest Exp TTM
$0
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$11,883,000
EBITDA
$-170,028,000
Free Cash Flow
—
Enterprise Value
$664,612,608
Total Cash
$171,592,992
Total Debt
$1,437,000
Shares Out
37,143,940
Trailing EPS
$-0.14
Book Value
$4.77
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,844,000 | -152,632,000 | -153,942,000 | 240,293,000 | 37,281,000 | 203,012,000 | -71,532,000 |
| Dec 2024 | — | — | — | 35,617,000 | 51,096,000 | -15,479,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.63
Max Pain — expiry 2027-02-19
max pain strike: $15.00 · spot: $13.99 · call oi: 2,059 · put oi: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $514.74M | $9.27 | — |
| INDP | Indaptus Therapeutics, Inc. | $512.98M | $3.85 | — |
| EOLS | Evolus, Inc. | $526.42M | $7.97 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $529.25M | $8.01 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $508.26M | $51.80 | — |
News headlines (Yahoo Finance, 1h cache)
Crescent Biopharma Announces Grants of Inducement Awards
2026-09-25 20:15 · Yahoo
Crescent Biopharma to Present at September Investor Conferences
2026-09-03 11:30 · Yahoo
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-07-16 20:01 · Yahoo
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-15 01:45 · Yahoo
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-14 20:01 · Yahoo
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
2026-09-03 20:51 · Yahoo
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-30 11:35 · Yahoo
Crescent Biopharma to Present at June Investor Conferences
2026-06-02 20:15 · Yahoo
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-29 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.